Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alcon Inc. stock logo
ALC
Alcon
$89.56
-3.3%
$91.20
$77.54
$101.10
$44.17B1.071.46 million shs1.83 million shs
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$12.96
-9.7%
$16.06
$12.91
$21.69
$4.57B0.49675,285 shs1.11 million shs
Genmab A/S stock logo
GMAB
Genmab A/S
$19.24
+2.2%
$20.76
$18.48
$30.50
$12.73B0.98973,396 shs1.72 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alcon Inc. stock logo
ALC
Alcon
-0.06%+1.47%-1.69%+10.92%+13.29%
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
+1.54%-8.52%-9.58%-20.33%-12.67%
Genmab A/S stock logo
GMAB
Genmab A/S
+0.86%-4.08%-18.03%-10.38%-37.18%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alcon Inc. stock logo
ALC
Alcon
3.3127 of 5 stars
3.45.01.70.01.80.81.3
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
3.9006 of 5 stars
4.12.00.00.02.30.03.8
Genmab A/S stock logo
GMAB
Genmab A/S
3.857 of 5 stars
4.33.00.00.02.00.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alcon Inc. stock logo
ALC
Alcon
2.73
Moderate Buy$105.6017.91% Upside
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.25
Hold$18.9145.86% Upside
Genmab A/S stock logo
GMAB
Genmab A/S
2.69
Moderate Buy$41.33114.83% Upside

Current Analyst Ratings Breakdown

Latest BLCO, ALC, and GMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $15.00
4/1/2025
Genmab A/S stock logo
GMAB
Genmab A/S
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform
3/31/2025
Alcon Inc. stock logo
ALC
Alcon
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$108.00 ➝ $112.00
3/28/2025
Alcon Inc. stock logo
ALC
Alcon
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$115.00 ➝ $120.00
3/28/2025
Alcon Inc. stock logo
ALC
Alcon
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $110.00
3/28/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$24.00 ➝ $15.00
3/27/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$18.00
3/25/2025
Alcon Inc. stock logo
ALC
Alcon
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
3/25/2025
Alcon Inc. stock logo
ALC
Alcon
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/25/2025
Alcon Inc. stock logo
ALC
Alcon
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
3/20/2025
Alcon Inc. stock logo
ALC
Alcon
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$107.00 ➝ $107.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alcon Inc. stock logo
ALC
Alcon
$9.91B4.46$5.20 per share17.23$41.81 per share2.14
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.79B0.95$1.54 per share8.41$18.57 per share0.70
Genmab A/S stock logo
GMAB
Genmab A/S
$21.53B0.59$1.30 per share14.80$8.04 per share2.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alcon Inc. stock logo
ALC
Alcon
$974M$2.0538.2727.222.2911.89%7.17%5.03%5/12/2025 (Estimated)
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$0.91N/A13.500.85-6.62%3.35%1.66%4/30/2025 (Estimated)
Genmab A/S stock logo
GMAB
Genmab A/S
$1.14B$1.7411.0610.812.6536.30%16.78%13.79%5/1/2025 (Estimated)

Latest BLCO, ALC, and GMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Genmab A/S stock logo
GMAB
Genmab A/S
$0.26N/AN/AN/AN/AN/A
4/30/2025N/A
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.06N/AN/AN/A$1.15 billionN/A
2/25/2025Q4 2024
Alcon Inc. stock logo
ALC
Alcon
$0.70$0.72+$0.02$0.57$2.47 billion$2.48 billion
2/19/2025Q4 2024
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.23$0.25+$0.02-$0.01$1.26 billion$1.28 billion
2/12/2025Q4 2024
Genmab A/S stock logo
GMAB
Genmab A/S
$0.28$0.57+$0.29$0.85$884.02 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alcon Inc. stock logo
ALC
Alcon
$0.260.29%+33.89%12.68%N/A
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alcon Inc. stock logo
ALC
Alcon
0.21
2.57
1.60
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
Genmab A/S stock logo
GMAB
Genmab A/S
N/A
5.25
5.24

Institutional Ownership

CompanyInstitutional Ownership
Alcon Inc. stock logo
ALC
Alcon
53.86%
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
Genmab A/S stock logo
GMAB
Genmab A/S
7.07%

Insider Ownership

CompanyInsider Ownership
Alcon Inc. stock logo
ALC
Alcon
1.52%
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.15%
Genmab A/S stock logo
GMAB
Genmab A/S
1.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alcon Inc. stock logo
ALC
Alcon
25,200493.24 millionN/AOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500352.47 million351.94 millionOptionable
Genmab A/S stock logo
GMAB
Genmab A/S
1,660661.77 million651.58 millionOptionable

Recent News About These Companies

Genmab downgraded to Underperform from Market Perform at Bernstein
Morgan Stanley Sticks to Its Hold Rating for Genmab (GMAB)
Genmab downgraded by Bernstein amid Darzalex concerns
Genmab announces EC marketing authorization for TIVDAK
Transactions in connection with share buy-back program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alcon stock logo

Alcon NYSE:ALC

$89.56 -3.03 (-3.27%)
Closing price 03:59 PM Eastern
Extended Trading
$89.60 +0.05 (+0.05%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$12.96 -1.39 (-9.66%)
Closing price 03:58 PM Eastern
Extended Trading
$12.98 +0.02 (+0.16%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$19.24 +0.42 (+2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$19.24 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.